latest news releases from the newsroom
Artificial Life, Inc.
VfB Stuttgart and Artificial Life Launch the Official VfB Stuttgart Mobile Game
LOS ANGELES, BERLIN and HONG KONG, Sept. 30, 2009 (GLOBE NEWSWIRE) -- Artificial Life, Inc., (OTCBB:ALIF), (http://www.artificial-life.com), and VfB Stuttgart announced the recent release of VfB Stuttgart 2009/10 - The Official Mobile Game for the traditional soccer club in the German League. The game is already available on designated channels in Germany, Switzerland and Austria.
XOMA Presents Results Demonstrating Novel Mechanism of Action for XOMA 052 in Regulating IL-1 Beta Levels
VIENNA, Austria, Sept. 30, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced new data demonstrating the unique regulatory mechanism of action of XOMA 052, a potent antibody drug candidate that inhibits the inflammatory cytokine interleukin-1 beta (IL-1 beta). XOMA 052 is currently under study for the treatment of patients with Type 2 diabetes, cardiovascular and other diseases. The new results were reported at the European Association for the Study of Diabetes medical conference in Vienna today.
Discovery Laboratories, Inc.
Discovery Labs and FDA Establish Path for Potential Surfaxin Approval
WARRINGTON, Pa., Sept. 30, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) held a teleconference on September 29, 2009 with the U.S. Food and Drug Administration (FDA). The meeting established an approach to potentially resolve the remaining primary issue that Discovery Labs must address to gain U.S. marketing approval of Surfaxin(R) (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. The meeting focused on Discovery Labs' plans regarding optimization and final method validation of its fetal rabbit Biological Activity Test (BAT, a quality control and stability release test) and a proposed limited Surfaxin clinical trial design, which would simultaneously employ the newly-optimized BAT.